King Denied Injunction In Levothyroxine Suit Against FDA; Mylan Faces Exclusivity Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
A D.C. federal judge declines to stay or temporarily revoke FDA approval of supplemental NDAs allowing Alara’s Levo-T and Jerome Stevens’ Unithroid to claim equivalence to Levoxyl. Mylan also is protesting FDA approval of the supplemental NDAs because the company believes it is entitled to 180-day generic exclusivity for Levoxyl.
You may also be interested in...
Valeant Wins Stay On Efudex Generic
In an abrupt reversal, FDA tells court it will review approval of Spear’s fluorouracil ANDA and make a decision by May 30.
Valeant Wins Stay On Efudex Generic
In an abrupt reversal, FDA tells court it will review approval of Spear’s fluorouracil ANDA and make a decision by May 30.
Mylan/King Merger Brings Another Twist To Levothyroxine Generics
Mylan's launch of a generic version of the thyroid hormone levothyroxine will not be affected by the proposed acquisition of Levoxyl-manufacturer King Pharmaceuticals, Mylan maintained during a July 26 conference call